Search

Displaying results 771 - 780 of 2817 in total
  1. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    [A229083] Available as oral tablets or long-acting intramuscular injections, flupentixol is marketed under brand names such as Depixol and Fluanxol.

    Categories: P-glycoprotein inhibitors
  2. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 Inducers
  3. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a similar indication as approved by the FDA.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  4. Drug

    Cupric oxide

    go.drugbank.com/drugs/DB11134
    Approved

    Cupric oxide, or copper (II) oxide, is an inorganic compound with the chemical formula CuO. Cupric oxide is used as a precursor in many copper-containing products such as wood preservatives and ceramics. Cupric oxide may be found in over...

    Mixtures: Virt-Pn, Virt-PN
  5. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  6. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the

  7. Drug

    Spaglumic acid

    go.drugbank.com/drugs/DB08835
    Investigational

    Specifically spaglumic acid is approved in Portugal under the brand name Naabak and in Greece under the brand name Naaxia for use in patients with allergic conjunctivitis.

  8. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].

  9. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.

  10. Drug

    Avacincaptad pegol

    go.drugbank.com/drugs/DB15165
    ApprovedInvestigational

    [A260801] Avacincaptag pegol was approved by the FDA on August 4, 2023, under the brand name IZERVAY for the treatment of GA secondary to AMD.